Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,551 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Active, not recruiting Phase 2 Interventional

Rapamycin - Effects on Alzheimer's and Cognitive Health

NCT04629495
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Rapamycin, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
55 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Phase 4 Interventional

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

NCT00303277
View directory record Official record
Conditions
Alzheimer's Disease, Aging
Interventions
simvastatin, pravastatin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT01767129
View directory record Official record
Conditions
Dyskinesia, Parkinson's Disease
Interventions
AVP-923-45, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 12, 2026, 1:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease

NCT00032812
View directory record Official record
Conditions
Parkinson Disease, Healthy
Interventions
Raclopride
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Health-Kit Enabled Mobile App for Tobacco Cessation

NCT06292130
View directory record Official record
Conditions
Cigarette Smoking
Interventions
refresh
Behavioral
Lead sponsor
Pro-Change Behavior Systems
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
South Kingstown, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

NCT01018056
View directory record Official record
Conditions
Tourette Syndrome
Interventions
D-serine, Riluzole, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 12, 2026, 1:44 PM EDT
Terminated Phase 4 Interventional

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

NCT00477802
View directory record Official record
Conditions
Parkinson Disease
Interventions
Botulinum Toxin Type A, Placebo
Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2009 · Synced Oct 12, 2026, 1:44 PM EDT
Not listed Not applicable Interventional

NRC:Improving Healthcare for Cognitively Impaired Elders and Their Caregivers

NCT03289377
View directory record Official record
Conditions
Alzheimer Disease, Nurse Training
Interventions
RDAD Training
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 12, 2026, 1:44 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

NCT04378075
View directory record Official record
Conditions
Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions
Vatiquinone, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Up to 20 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
San Diego, California • Stanford, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 12, 2026, 1:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Aging Project--Kansas University

NCT00267124
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment

NCT01876823
View directory record Official record
Conditions
Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions
es-citalopram, Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

NCT00139880
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Parcopa
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
40 Years and older
Timeline
2005
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 12, 2026, 1:44 PM EDT
Not listed Not applicable Interventional

Home-based Neuromodulation to Target Depression And Memory Symptoms in Older Adults

NCT05976659
View directory record Official record
Conditions
Major Depressive Disorder, Alzheimer Disease, Dementia, Nervous System Diseases, Memory Disorders, Depressive Disorder
Interventions
Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 12, 2026, 1:44 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808

NCT01723488
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[F18] T808
Radiation
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 12, 2026, 1:44 PM EDT
Completed No phase listed Observational

Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD

NCT00491842
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

NCT01839656
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
21 Days to 210 Days
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Stanford, California • Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 12, 2026, 1:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT06789445
View directory record Official record
Conditions
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
Interventions
OpCT-001
Biological
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 1:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ASSESS ALL ALS Study

NCT06578195
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 12, 2026, 1:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy

NCT02269865
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

NCT02849457
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Early Vigabatrin, Delayed Vigabatrin (Placebo)
Drug
Lead sponsor
Martina Bebin
Other
Eligibility
1 Day to 6 Months
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 12, 2026, 1:44 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

NCT02614131
View directory record Official record
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 12, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

NCT03896295
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
M281
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 12, 2026, 1:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Japanese Bridging Study

NCT01057030
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BMS-708163, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 12, 2026, 1:44 PM EDT
Completed No phase listed Observational

Parkinson's Genes and Environment Study

NCT00367900
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
50 Years and older
Enrollment
3,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 12, 2026, 1:44 PM EDT